Securing Updated News Today

TSCA/FIFRA/TRI - Lynn L. Bergeson Authors “EPA Targets Asbestos,” Chemical Processing:On May 6, 2022, the U.S. Environmental Protection Agency (EPA) proposed reporting and...

EPA Amends Several TSCA Section 4 Test Orders For Chemicals Undergoing Risk Evaluation. EPA Resolves Case Involving Export Of Carbon Nanomaterial In Violation Of TSCA Section 12b And Notice Of Export Requirements. EPA Proposes To Update CBI Requirements Under TSCA.

In a win for the AAFP’s advocacy to promote and reinforce administrative simplification, HHS has withdrawn a harmful rule that threatened to add new burdens for physicians.

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and...

The U.S. Department of Health and Human Services issued final rule withdrawing Securing Updated and Necessary Statutory Evaluations Timely SUNSET rule, enacted late Trump administration. Required HHS rules reviewed every 10 years or be automatically repealed.

The Department of Health and Human Services has withdrawn a Trump-era rule that mandated the sunset of any rule more than 10 years old unless it was reviewed within five years. Under the Biden Administration, HHS delayed implementation of the Securing Updated and Necessary Statutory Evaluations Timely, or SUNSET rule that was originally scheduled to take effect on March 22.

The House Committee on Oversight and Reform is asking nine of the largest pharmacy benefit managers and insurers whether they readily provide birth control at no cost to patients.

HHS final notice withdrawing the rule lists problems with the way it was made

FDA Acknowledges Shortcomings Leading to Infant Formula Shortage, Finance Committee Releases Bipartisan Draft Proposal for Telehealth Policies for Mental Health. CMS Holds Webinar on Medicaid and the End of the PHE. Covid-19 vaccines for children under 5 and more Health news

Top Republicans on the committee signal the infant formula crisis could hamper efforts to quickly reauthorize FDA user fees.